DRG TM-CA 72-4 ELISA Kit used in NYU Winthrop Hospital Cancer Study!
DRG is proud to announce that our TM-CA 72-4 ELISA Kit (EIA-5071) has been used in a recent cancer study done by NYU Winthrop Hospital. The DRG TM-CA 72-4 ELISA Kit is for sale in the United States as an RUO product and is CE marked for global sales. Please see details on the study below, as well as a link to the article. See an excerpt from the article abstract below:
“Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of human adenocarcinomas. Using the DRG TM-CA72-4, [researchers] quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types.
Materials and Methods: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer’s instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated.
Results: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients.
Conclusion: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas.”
If you are interested in purchasing or finding more information on DRG’s TM-CA 72-4 ELISA Kit (EIA-5071) you can find a link to it here in our new Ecommerce store: https://store.drg-international.com/shop/tm-ca-72-4-elisa.asp
You can also call +1-973-564-7555 or email [email protected] for more information.
The article is used by permission from the International Institute of Anticancer Research (IIAR).
The article original source publication is: Anticancer Research, Vol. 37, No. 7, pp. 3649-3656.
http://ar.iiarjournals.org/content/37/7/3649 (abstract only)
http://ar.iiarjournals.org/content/37/7/3649.long (full article)
http://ar.iiarjournals.org/content/37/7/3649.full.pdf (pdf version)
Latest posts by Gregory C. Guest (see all)
- NEW AMH (Anti-Mullerian Hormone) ELISA Available at DRG! - May 14, 2018
- DRG SUCCESSFULLY EXHIBITS AT MEDLAB DUBAI 2018! - February 28, 2018
- DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil - November 22, 2017
News and Updates
DRG is proud to announce a new AMH ELISA (EIA-6053), a quantitative and sensitive ELISA for the measurement of Anti Müllerian Hormone. AMH Assay Characteristics EIA-6053 Assay Principle: Sandwich ELISA Dynamic Range: 0.02 - 20 ng/mL Total Assay Time:...read more
The DRG Group recently exhibited at the largest healthcare exhibition & congress in the Middle East: MEDLAB DUBAI from February 5 - 8, 2018 with great success! In addition to the presentation of several new assays DRG offered live demonstrations of our...read more
DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil
DRG is proud to announce the new partnership with Serion-Brazil and looks forward to a longstanding and successful business relationship! Mr. Gustavo Ruales, DRG International's Latin American Sales Manager, also attended the exhibition to support...read more